WO1991004058A3 - Treatment of conditions and disease - Google Patents

Treatment of conditions and disease Download PDF

Info

Publication number
WO1991004058A3
WO1991004058A3 PCT/CA1990/000306 CA9000306W WO9104058A3 WO 1991004058 A3 WO1991004058 A3 WO 1991004058A3 CA 9000306 W CA9000306 W CA 9000306W WO 9104058 A3 WO9104058 A3 WO 9104058A3
Authority
WO
WIPO (PCT)
Prior art keywords
disease
treated
hyaluronic acid
treatment
conditions
Prior art date
Application number
PCT/CA1990/000306
Other languages
French (fr)
Other versions
WO1991004058A2 (en
Inventor
Rudolf Edgar Falk
Samuel S Asculai
Original Assignee
Norpharmco Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=4140639&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO1991004058(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to DE69024039T priority Critical patent/DE69024039T3/en
Priority to KR1019910700514A priority patent/KR920700697A/en
Priority to EP90914108A priority patent/EP0445255B2/en
Priority to US07/675,908 priority patent/US6069135A/en
Priority to DK90914108T priority patent/DK0445255T4/en
Priority to RO148511A priority patent/RO112812B1/en
Priority to BR909006924A priority patent/BR9006924A/en
Priority to SU4895848/A priority patent/RU2146139C1/en
Application filed by Norpharmco Inc filed Critical Norpharmco Inc
Publication of WO1991004058A2 publication Critical patent/WO1991004058A2/en
Priority to FI912470A priority patent/FI912470A0/en
Priority to NO91911952A priority patent/NO911952L/en
Publication of WO1991004058A3 publication Critical patent/WO1991004058A3/en
Priority to US08/290,848 priority patent/US5910489A/en
Priority to US08/462,615 priority patent/US5830882A/en
Priority to US08/466,778 priority patent/US5962433A/en
Priority to US08/468,329 priority patent/US5824658A/en
Priority to HK44797A priority patent/HK44797A/en
Priority to US10/628,999 priority patent/US20040019011A1/en
Priority to US11/245,816 priority patent/US20060128655A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/10—Sulfides; Sulfoxides; Sulfones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/503—Pyridazines; Hydrogenated pyridazines spiro-condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Inorganic Chemistry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

A combination for administration to a mammal which combination employs a therapeutically effective amount of a medicinal and/or therapeutic agent to treat a disease or condition and an amount of hyaluronic acid and/or salts thereof and/or homologues, analogues, derivatives, complexes, esters, fragments and subunits of hyaluronic acid sufficient to facilitate the agent's penetration through the tissue (including scar tissue) at the site to be treated, through the cell membranes into the individual cells to be treated.
PCT/CA1990/000306 1989-09-21 1990-09-18 Treatment of conditions and disease WO1991004058A2 (en)

Priority Applications (17)

Application Number Priority Date Filing Date Title
DE69024039T DE69024039T3 (en) 1989-09-21 1990-09-18 USE OF HYALURONIC ACID IN COMBINATION WITH ASCORBIC ACID, ANTITUARY AGENTS AND / OR NSAIDS FOR TREATING CANCER
KR1019910700514A KR920700697A (en) 1989-09-21 1990-09-18 Method for treating tumor-related diseases in mammals using complex consisting of drug for treating disease and hyaluronic acid
EP90914108A EP0445255B2 (en) 1989-09-21 1990-09-18 USE OF HYALURONIC ACID IN COMBINATION WITH ASCORBIC ACID, ANTITUMOUR AGENTS AND/OR NSAIDs FOR TREATING CANCER
US07/675,908 US6069135A (en) 1989-09-21 1990-09-18 Use of hyaluronic acid or its derivatives to enhance delivery of therapeutic agents
DK90914108T DK0445255T4 (en) 1989-09-21 1990-09-18 Use of hyaluronic acid in combination with ascorbic acid, antitumor agents and / or NSAIDs for the treatment of cancer
RO148511A RO112812B1 (en) 1989-09-21 1990-09-18 Method of treating diseases or health states and composition for treatment
BR909006924A BR9006924A (en) 1989-09-21 1990-09-18 FORMULATION FOR THE TREATMENT OF SYMPTOMS AND DISEASES, USE OF FORMULATION FOR THE TREATMENT OF SYMPTOMS AND DISEASES, METHOD FOR THE TREATMENT OF SYMPTOMS AND DISEASES, DISTRIBUTION OF MEDICINAL AND THERAPEUTIC AGENTS FOR THE TREATMENT OF SYMPTOMS AND DISEASES IN COMBINATION
SU4895848/A RU2146139C1 (en) 1989-09-21 1990-09-18 Medical care of states and diseases, combinations and compositions usable in medicine, method and combinations for stimulating activity of macrophages
NO91911952A NO911952L (en) 1989-09-21 1991-05-21 TREATMENT OF CONDITIONS AND DISEASES AND AGENTS THEREOF.
FI912470A FI912470A0 (en) 1989-09-21 1991-05-21 BEHANDLING AV HAELSOTILLSTAOND OCH SJUKDOMAR.
US08/290,848 US5910489A (en) 1990-09-18 1993-02-16 Topical composition containing hyaluronic acid and NSAIDS
US08/462,615 US5830882A (en) 1989-09-21 1995-06-05 Compositions containing a form of hyaluronic acid and a medicinal agent for treating acne in mammals and methods for administration of such composition
US08/466,778 US5962433A (en) 1990-09-18 1995-06-06 Topical composition containing hyaluronic acid and NSAIDS
US08/468,329 US5824658A (en) 1990-09-18 1995-08-07 Topical composition containing hyaluronic acid and NSAIDS
HK44797A HK44797A (en) 1989-09-21 1997-04-10 Treatment of conditions and disease
US10/628,999 US20040019011A1 (en) 1989-09-21 2003-07-28 Treatment of conitions and disease
US11/245,816 US20060128655A1 (en) 1989-09-21 2005-10-07 Use of hyaluronic acid or its derivatives to enhance delivery of antineoplastic agents

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CA000612307A CA1340994C (en) 1989-09-21 1989-09-21 Treatment of conditions and disease
CA612,307 1989-09-21

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US83867492A Continuation-In-Part 1990-09-18 1992-02-21

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US07/675,908 Continuation-In-Part US6069135A (en) 1989-09-21 1990-09-18 Use of hyaluronic acid or its derivatives to enhance delivery of therapeutic agents
US08/467,994 Continuation-In-Part US6218373B1 (en) 1992-02-20 1995-06-06 Formulations containing hyaluronic acid

Publications (2)

Publication Number Publication Date
WO1991004058A2 WO1991004058A2 (en) 1991-04-04
WO1991004058A3 true WO1991004058A3 (en) 1991-09-19

Family

ID=4140639

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CA1990/000306 WO1991004058A2 (en) 1989-09-21 1990-09-18 Treatment of conditions and disease

Country Status (26)

Country Link
US (14) US6069135A (en)
EP (2) EP0445255B2 (en)
JP (1) JP3256761B2 (en)
KR (1) KR920700697A (en)
CN (1) CN1101228C (en)
AP (1) AP175A (en)
AT (2) ATE131068T1 (en)
AU (3) AU6433090A (en)
BR (1) BR9006924A (en)
CA (2) CA1340994C (en)
DE (2) DE69034018T2 (en)
DK (2) DK0656213T3 (en)
ES (2) ES2186693T3 (en)
FI (1) FI912470A0 (en)
HK (2) HK44797A (en)
HU (2) HU220758B1 (en)
IL (1) IL95745A (en)
IN (1) IN171745B (en)
LT (1) LT3545B (en)
NO (1) NO911952L (en)
RO (1) RO112812B1 (en)
RU (1) RU2146139C1 (en)
SG (1) SG49658A1 (en)
SK (1) SK459890A3 (en)
WO (1) WO1991004058A2 (en)
ZA (1) ZA907564B (en)

Families Citing this family (237)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1340994C (en) * 1989-09-21 2000-05-16 Rudolf Edgar Dr. Falk Treatment of conditions and disease
DE69132145T2 (en) 1990-02-13 2000-09-21 Ethicon Inc PERITONEAL EFFECTIVE DRUGS
CA2061566C (en) * 1992-02-20 2002-07-09 Rudolf E. Falk Treatment of disease employing hyaluronic acid and nsaids
US5639738A (en) * 1992-02-20 1997-06-17 Hyal Pharmaceutical Corporation Treatment of basal cell carcinoma and actinic keratosis employing hyaluronic acid and NSAIDs
CA2061703C (en) * 1992-02-20 2002-07-02 Rudolf E. Falk Formulations containing hyaluronic acid
DE69125595T2 (en) * 1990-10-18 1997-11-13 Shiseido Co Ltd COMBINATION OF HYALURONIC ACID WITH A MEDICAL INGREDIENT, AND ITS PRODUCTION
US5733891A (en) * 1990-10-18 1998-03-31 Shiseido Co., Ltd. Compound for medicinal ingredient and hyaluronic acid and process for producing the same
US5610148A (en) * 1991-01-18 1997-03-11 University College London Macroscopically oriented cell adhesion protein for wound treatment
US5629287A (en) * 1991-01-18 1997-05-13 University College London Depot formulations
EP0503583A1 (en) * 1991-03-12 1992-09-16 Takeda Chemical Industries, Ltd. Composition for sustained release of erythropoietin
US5416071A (en) * 1991-03-12 1995-05-16 Takeda Chemical Industries, Ltd. Water-soluble composition for sustained-release containing epo and hyaluronic acid
US6432405B1 (en) * 1991-03-15 2002-08-13 Duke University Method of inhibiting HIV infection with CD44 and anti-CD44 antibodies
CA2079205C (en) * 1992-09-25 1998-02-10 Rudolf Edgar Falk Use of hyaluronic acid and forms to prevent arterial restenosis
US5990095A (en) 1991-07-03 1999-11-23 Hyal Pharmaceutical Corporation Use of hyaluronic acid and forms to prevent arterial restenosis
WO1994007505A1 (en) * 1991-07-03 1994-04-14 Norpharmco Inc. Use of hyaluronic acid and forms to prevent arterial restenosis
US5817644A (en) * 1991-07-03 1998-10-06 Hyal Pharmaceutical Corporation Targeting of dosages of medicine and therapeutic agents
CA2122519C (en) * 1994-04-29 2001-02-20 Rudolf Edgar Dr. Falk Cancer treatment and metastasis prevention
US6022866A (en) * 1991-07-03 2000-02-08 Hyal Pharmaceutical Corporation Use of hyaluronic acid and forms to prevent arterial restenosis
DE69227607T2 (en) * 1991-07-10 1999-04-15 Takeda Chemical Industries Ltd Medicines based on hyaluronic acid
FR2686899B1 (en) * 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa NOVEL BIOLOGICALLY ACTIVE POLYPEPTIDES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
CA2061567C (en) * 1992-02-20 1998-02-03 Rudolf E. Falk Use of hyaluronic acid to repair ischemia reperfusion damage
CA2130762C (en) * 1994-08-24 1999-07-06 Eva Anne Turley Treatment of disease and conditions associated with macrophage infiltration
US5438075A (en) 1993-03-30 1995-08-01 Skubitz; Keith M. Oral glutamine to reduce stomatitis
CA2094203A1 (en) * 1993-04-16 1994-10-17 Derek A. Willoughby Inhibition of angiogenesis
EP2226085B1 (en) * 1993-07-19 2013-11-27 Angiotech Pharmaceuticals, Inc. Anti-angiogenic compositions and methods of use
AU3159595A (en) * 1994-08-30 1996-03-22 Hyal Pharmaceutical Corporation Hyaluronic acid and derivatives for modulation of cellular activity
US7091181B2 (en) 1994-12-12 2006-08-15 Omeros Corporation Method of inhibition of pain and inflammation during surgery comprising administration of soluble TNF receptors
JPH10510540A (en) 1994-12-12 1998-10-13 オメロス メディカル システムズ，インコーポレーテッド Irrigation solutions and methods for controlling pain, inflammation and convulsions
CN1160115C (en) * 1994-12-12 2004-08-04 奥默罗斯公司 Irrigation solution and method for inhibition of pain, inflammation
US6492332B1 (en) 1995-12-12 2002-12-10 Omeros Corporation Irrigation solution and methods for inhibition of tumor cell adhesion, pain and inflammation
KR100517210B1 (en) * 1994-12-12 2006-06-07 오메로스 코포레이션 Infusion solution for pain, inflammation and spasm
CA2154103C (en) * 1995-07-18 1998-02-24 Samuel Simon Asculai Treatment of mucous membrane disease, trauma or condition and for the relief of pain
JP3419785B2 (en) * 1995-09-28 2003-06-23 サングスタット メディカル コーポレイション Use of hyaluronic acid as an immunosuppressant
KR19990066967A (en) * 1995-10-23 1999-08-16 둘헌티 브리안 Gene therapy for treating abnormal retinal angiogenesis and hyaluronic acid used as a DNA carrier for VEGF antisense
US5652273A (en) * 1995-11-30 1997-07-29 Henry; James Reduction of hair growth
WO1997020564A1 (en) * 1995-12-01 1997-06-12 Hyal Pharmaceutical Corporation Targeting of dosages of medicine and therapeutic agents and other glycosaminoglycans (gags)
US6413961B1 (en) 1995-12-12 2002-07-02 Omeros Medical Systems, Inc. Irrigation solution and method for inhibition of pain and inflammation
CA2166155C (en) * 1995-12-27 2008-02-05 Eva Anne Turley Agents binding to hyaluronic acid binding domains and the use thereof
WO1997025051A1 (en) * 1996-01-11 1997-07-17 Hyal Pharmaceutical Corporation Oral administration of effective amounts of forms of hyaluronic acid
US6875753B1 (en) * 1996-03-14 2005-04-05 The Governors Of The University Of Alberta Methods for cell mobilization using in vivo treatment with hyaluronan (HA)
US20050113335A1 (en) * 1996-04-02 2005-05-26 Pilarski Linda M. Methods for cell mobilization using in vivo treatment with hyaluronan (HA)
US5939047A (en) * 1996-04-16 1999-08-17 Jernberg; Gary R. Local delivery of chemotherapeutic agents for treatment of periodontal disease
US6787530B1 (en) * 1996-08-23 2004-09-07 Monash University Use of pregnane-diones as analgesic agents
DE69732308T2 (en) * 1996-09-27 2005-06-02 Jagotec Ag DRUG DISPOSAL SYSTEM WITH HYALURONIC ACID
US6451784B1 (en) * 1996-12-30 2002-09-17 Battellepharma, Inc. Formulation and method for treating neoplasms by inhalation
CA2205692A1 (en) * 1997-05-16 1998-11-16 Hyal Pharmaceutical Corporation Method of administration for a therapeutic agent utilizing suitable forms of hyaluronic acid and combinations with electroporation
CA2205771C (en) * 1997-05-22 2002-05-14 Hyal Pharmaceutical Corporation Improved delivery of disease modifiers
US6123957A (en) * 1997-07-16 2000-09-26 Jernberg; Gary R. Delivery of agents and method for regeneration of periodontal tissues
US5938658A (en) * 1997-12-02 1999-08-17 Tu; Hosheng Device and methods for treating canker sores by RF ablation
US7070799B1 (en) 1998-02-10 2006-07-04 Generex Pharmaceuticals, Inc. Method for administering insulin to the buccal region
US6017545A (en) * 1998-02-10 2000-01-25 Modi; Pankaj Mixed micellar delivery system and method of preparation
CN1140272C (en) 1998-04-03 2004-03-03 味之素株式会社 Antitumor agents
US7799766B2 (en) * 1998-04-08 2010-09-21 Theta Biomedical Consulting & Development Co., Inc. Composition for treating hormonally-dependent cancers
US6984667B2 (en) * 1998-04-08 2006-01-10 Theta Biomedical Consulting And Development Co. Synergistic proteoglycan compositions for inflammatory conditions
GB9810127D0 (en) * 1998-05-13 1998-07-08 Ml Lab Plc Prevention of surgical adhesions
US6391861B1 (en) 1998-05-14 2002-05-21 The Trustees Of Columbia University In The City Of New York Method for the prevention of tissue elastic fiber injury
US6663874B2 (en) 1998-11-02 2003-12-16 Victor Stevens Composition to alleviate pain and topical method of applying same
EP1140006B1 (en) * 1998-12-23 2003-07-23 Esparma GmbH Skin protection agents containing a fragment mixture produced from hyaluronic acid by hydrolysis
AU773984B2 (en) * 1999-01-13 2004-06-10 Alchemia Oncology Pty Limited A composition and method for the enhancement of the efficacy of drugs
NZ512676A (en) 1999-01-13 2003-01-31 Meditech Res Ltd A composition and method for the enhancement of the efficacy of drugs
WO2000045804A2 (en) * 1999-02-04 2000-08-10 Genzyme Corporation Use of a polyanionic polysaccharide solution for the prevention of abscess formation
DK1091750T3 (en) * 1999-02-26 2009-12-21 Maas Biolab Llc Cerebrospinal and vascular pharmaceutical composition and process for their preparation
EP1206283A2 (en) * 1999-05-17 2002-05-22 Aesgen, Inc. Improved cellular uptake of bioactive agents
JP4450456B2 (en) * 1999-09-27 2010-04-14 株式会社マルハニチロ水産 Sebum production inhibitor
SE9904121D0 (en) * 1999-11-15 1999-11-15 Gustaf Jederstroem Hydrophobic biomolecular structure
HUP0300627A3 (en) * 1999-12-13 2005-11-28 Bioniche Life Sciences Inc Bel Therapeutically useful synthetic oligonucleotides
CA2395493C (en) * 1999-12-28 2010-06-22 Bioniche Life Sciences Inc. Hyaluronic acid in the treatment of cancer
GB0003048D0 (en) * 2000-02-11 2000-03-29 Dealler Stephen F The therapeutic use of polysulphonated polyglycosides or other polyanionic compounds in autism
DE60100866T2 (en) 2000-04-07 2004-07-29 Laboratoire Medidom S.A. Ophthalmic medicinal product containing cyclosporine, hyaluronic acid and polysorbate
US20050100991A1 (en) * 2001-04-12 2005-05-12 Human Genome Sciences, Inc. Albumin fusion proteins
CA2747325A1 (en) * 2000-04-12 2001-10-25 Human Genome Sciences, Inc. Albumin fusion proteins
WO2001078721A1 (en) * 2000-04-13 2001-10-25 Mayo Foundation For Medical Education And Research Aβ42 LOWERING AGENTS
WO2001093846A2 (en) * 2000-05-23 2001-12-13 The Trustees Of Columbia University In The City Of New York Method for treating respiratory disorders associated with pulmonary elastic fiber injury comprising the use of clycosaminoglycans
US6221166B1 (en) * 2000-06-07 2001-04-24 Simplus Systems Corporation Multi-thermal zone shielding apparatus
US6545007B2 (en) * 2000-11-17 2003-04-08 Idenix (Cayman) Limited Methods for inhibiting the transmission of HIV using topically applied substituted 6-benzyl-4-oxopyrimidines
WO2002030432A1 (en) * 2000-06-23 2002-04-18 Cambridgemed, Inc Agent for reduction of scar formation by using wound alkalinization
AUPQ879500A0 (en) * 2000-07-14 2000-08-10 Meditech Research Limited Hyaluronan as cytotoxic agent, drug presensitizer and chemo-sensitizer in the treatment of disease
US9066919B2 (en) * 2000-07-14 2015-06-30 Alchemia Oncology Pty Limited Hyaluronan as a chemo-sensitizer in the treatment of cancer
US7285284B2 (en) * 2000-09-08 2007-10-23 Kuhnau Stephen C Cosmetic composition, method of use and method of making
AU2001292929A1 (en) * 2000-09-26 2002-04-08 Temple University Of The Commonwealth System Of Higher Education Analgesic and glucosamine compositions
US6924273B2 (en) * 2000-10-03 2005-08-02 Scott W. Pierce Chondroprotective/restorative compositions and methods of use thereof
EP1333811A4 (en) * 2000-10-16 2004-03-03 Neopharm Inc Liposomal formulation of mitoxantrone
CN1131036C (en) * 2001-02-28 2003-12-17 中国人民解放军第三军医大学 Application of N-acetyl-D-aminoglucose in preparing medicines to suppress by-effect of radiotherapy and chemicotherapy
US20020172712A1 (en) * 2001-03-19 2002-11-21 Alan Drizen Antiemetic, anti-motion sustained release drug delivery system
AU2002258563A1 (en) * 2001-03-19 2002-10-03 Praecis Pharmaceuticals Incorporated Pharmaceutical formulations for sustained release
US20060198815A1 (en) * 2001-03-19 2006-09-07 Praecis Pharmaceuticals, Inc. Pharmaceutical formulations for sustained release
JP5024497B2 (en) * 2001-03-27 2012-09-12 キユーピー株式会社 Oral skin improving agent, skin improving method and food composition for skin improvement
US8403954B2 (en) 2001-05-22 2013-03-26 Sanostec Corp. Nasal congestion, obstruction relief, and drug delivery
US20030143191A1 (en) * 2001-05-25 2003-07-31 Adam Bell Chemokine beta-1 fusion proteins
US20030027867A1 (en) * 2001-06-29 2003-02-06 Myriad Genetics, Incorporated Use of R-NSAID compounds for anti-HIV treatment
CN100542612C (en) 2001-08-14 2009-09-23 特拉维夫大学未来技术研发有限公司 Lipoid glycosaminoglycans granule and the application in diagnosis and medicine for treatment thing and gene transmission thereof
AU2002325635C1 (en) * 2001-08-27 2008-09-25 Alchemia Oncology Pty Limited Improved therapeutic protocols
CN1578677A (en) * 2001-08-27 2005-02-09 美迪泰克研究有限公司 Improved therapeutic protocols
EP1444983B1 (en) * 2001-10-18 2015-09-16 Seikagaku Corporation Agents for treating inflammatory bowel diseases
WO2003041723A1 (en) * 2001-11-12 2003-05-22 Reinmueller Johannes Pharmaceutical applications of hyaluronic acid preparations
ES2425738T3 (en) 2001-12-21 2013-10-17 Human Genome Sciences, Inc. Albumin Fusion Proteins
US6806259B2 (en) 2001-12-21 2004-10-19 Soft Gel Technologies, Inc. Hyaluronic Acid in soft gel form
RU2213557C2 (en) * 2001-12-26 2003-10-10 Закрытое акционерное общество "Аксис" Pharmaceutical composition eliciting thrombolytic, anti-inflammatory and cytoprotective properties
US7993390B2 (en) * 2002-02-08 2011-08-09 Boston Scientific Scimed, Inc. Implantable or insertable medical device resistant to microbial growth and biofilm formation
US6887270B2 (en) * 2002-02-08 2005-05-03 Boston Scientific Scimed, Inc. Implantable or insertable medical device resistant to microbial growth and biofilm formation
US8506647B2 (en) * 2002-02-14 2013-08-13 Boston Scientific Scimed, Inc. System for maintaining body canal patency
CN1309392C (en) * 2002-02-15 2007-04-11 研究发展基金会 Hyaluronic acid mediated adenoviral transduction
FR2836336B1 (en) 2002-02-26 2004-08-27 Diana Ingredients USE IN A COSMETIC TREATMENT OF A PHENOLIC FRACTION RICH IN DIHYDROCHALCONES
ATE361746T1 (en) * 2002-03-06 2007-06-15 Medical Res And Education Trus BOTANICAL EXTRACT WITH ANTI-CANCER ACTIVITY CONTAINING ISOLIQUIRITIGENIN
RU2308954C2 (en) * 2002-05-09 2007-10-27 Медиджинез Pharmaceutical composition containing blood plasma or serum for treatment of wounds
ITMI20020986A1 (en) * 2002-05-10 2003-11-10 Acraf COMPOSITION BASED ON DICLOFENAC FOR THE TOPICAL TREATMENT OF AFFECTIONS OF THE OROPHARINGOUS CABLE
RU2005102604A (en) * 2002-07-03 2005-09-10 Перикор Сайенс, Инк. (Us) COMPOSITION OF HYALURONIC ACID AND METHODS OF APPLICATION
ES2405287T3 (en) * 2002-08-01 2013-05-30 Eisai Inc. Improved treatment of glutamine cancer
US6979458B1 (en) 2002-09-11 2005-12-27 Kenneth A. Martin Beverage and additive for wellness
US20040254095A1 (en) * 2002-09-11 2004-12-16 Martin Kenneth A. Supplement for treating musculoskeletal disorders
US6660308B1 (en) 2002-09-11 2003-12-09 Kenneth A. Martin Beverage and additive for the ill
US20040253296A1 (en) * 2002-09-11 2004-12-16 Martin Kenneth A. Food bar for treating musculoskeletal disorders
US20040253227A1 (en) * 2002-09-11 2004-12-16 Martin Kenneth A. Perioperative multivitamin protein beverage and additive for use in preparing an individual for fast surgical recovery
US6900173B2 (en) * 2002-09-11 2005-05-31 Kenneth A. Martin Perioperative multivitamin protein bar for use in preparing an individual for fast surgical recovery
DE10246340A1 (en) * 2002-10-04 2004-04-29 Wohlrab, David, Dr. Combination preparation of hyaluronic acid and at least one local anesthetic and its use
WO2004071431A2 (en) * 2003-02-05 2004-08-26 Myriad Genetics, Inc. Method and composition for treating neurodegenerative disorders
US6946551B2 (en) 2003-03-12 2005-09-20 New Life Resources, Llc Preparation of hyaluronic acid from eggshell membrane
US20040180025A1 (en) * 2003-03-12 2004-09-16 New Life Resources, Llc Therapeutic, nutraceutical and cosmetic applications for eggshell membrane and processed eggshell membrane preparations
US20080063677A1 (en) * 2004-03-10 2008-03-13 New Life Resources, Llc Therapeutic, nutraceutical and cosmetic applications for eggshell membrane and processed eggshell membrane preparations
US20050136126A1 (en) * 2003-03-17 2005-06-23 Cambridgemed, Inc. Agent for reduction of scar formation by using wound alkalinization
JP4212970B2 (en) * 2003-06-30 2009-01-21 株式会社キーエンス Safety relay system
AU2004311577A1 (en) * 2003-07-11 2005-07-21 Myriad Genetics, Inc. Pharmaceutical methods, dosing regimes and dosage forms for the treatment of Alzheimer's disease
US6913968B2 (en) * 2003-07-30 2005-07-05 International Business Machines Corporation Method and structure for vertical DRAM devices with self-aligned upper trench shaping
US8236794B2 (en) * 2003-09-29 2012-08-07 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Treatment of mesothelioma
KR20070009527A (en) * 2003-09-30 2007-01-18 신테스 아게 츄어 Antimicrobial hyaluronic acid coatings for orthopedic implants
HUP0303313A2 (en) * 2003-10-09 2005-07-28 Richter Gedeon Vegyészeti Gyár Rt. Transdermal pharmaceutical compositions
WO2005044236A1 (en) * 2003-10-27 2005-05-19 Control Delivery Systems, Inc. Suspension delivery system for the sustained and controlled local release of pharmaceuticals
US20050100537A1 (en) * 2003-11-10 2005-05-12 Evans Gregory S. Methods and kits for reducing cellular damage, inhibiting free radical production, and scavenging free radicals in mammals
US20050147570A1 (en) * 2004-01-06 2005-07-07 Nordsiek Michael T. Methods of administering diclofenac compositions for treating photodamaged skin, rosacea and/or acne
WO2005070333A1 (en) 2004-01-13 2005-08-04 Orthobiologica, Inc. Drug delivery to a joint
DE102004002001A1 (en) * 2004-01-14 2005-08-11 Reinmüller, Johannes, Dr.med. Agent for the treatment of inflammatory diseases
US20050186269A1 (en) * 2004-02-25 2005-08-25 Udell Ronald G. Stabilized feverfew formulations
US8580315B2 (en) * 2004-03-10 2013-11-12 Esm Technologies, Llc Anti-inflammatory activity of eggshell membrane and processed eggshell membrane preparations
US7699783B2 (en) * 2004-04-08 2010-04-20 Techniscan, Inc. Method for imaging and treating a breast
WO2006001877A2 (en) * 2004-04-13 2006-01-05 Myriad Genetics, Inc. Combination treatment for neurodegenerative disorders comprising r-flurbiprofen
AR051429A1 (en) * 2004-04-20 2007-01-17 Stenti De Pirillo Haydee A OZONIZED PHARMACEUTICAL COMPOSITION AND METHODS TO OBTAIN IT
EP1745180A1 (en) * 2004-04-29 2007-01-24 Keystone Retaining Wall Systems, Inc. Veneers for walls, retaining walls and the like
JP2008503583A (en) * 2004-06-22 2008-02-07 プロ−ファーマシューティカルズ，インコーポレイティド Compositions and methods for co-delivery of anti-cancer agents, anti-angiogenic agents, and polysaccharides
DE102004030155B4 (en) * 2004-06-22 2020-04-23 Robert Bosch Gmbh Metering device and method for operating the same
WO2006020850A2 (en) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Pharmaceutical composition and method for treating neurodegenerative disorders
BRPI0514303A (en) * 2004-08-11 2008-06-10 Myriad Genetics Inc pharmaceutical composition and method for treating neurodegenerative disorders
WO2006020852A2 (en) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Pharmaceutical composition and method for treating neurodegenerative disorders
JP2008509935A (en) * 2004-08-13 2008-04-03 アンジオテック インターナショナル アーゲー Compositions and methods using hyaluronic acid and hyaluronic acid inhibitors
US7414021B2 (en) * 2004-10-01 2008-08-19 Vincent Carmine Giampapa Method and composition for restoration of age related tissue loss in the face or selected areas of the body
US20060275230A1 (en) 2004-12-10 2006-12-07 Frank Kochinke Compositions and methods for treating conditions of the nail unit
KR20070095921A (en) 2004-12-10 2007-10-01 탈리마 테라퓨틱스 인코포레이티드 Compositions and methods for treating conditions of the nail unit
US20060292250A1 (en) * 2005-06-23 2006-12-28 Suracell, Inc. Supplement composition and method of use for enhancement of anti-inflammation process
US7276257B2 (en) * 2005-07-22 2007-10-02 The Hong Kong University Of Science And Technology Schisandrin B preparation
KR20080039876A (en) * 2005-07-22 2008-05-07 미리어드 제네틱스, 인크. High drug load formulations and dosage forms
CN103784960A (en) 2005-07-27 2014-05-14 阿尔卡米亚肿瘤学股份有限公司 Therapeutic protocols using hyaluronan
US7323184B2 (en) * 2005-08-22 2008-01-29 Healagenics, Inc. Compositions and methods for the treatment of wounds and the reduction of scar formation
US20070048391A1 (en) * 2005-08-23 2007-03-01 Cambridgemed, Inc. Composition for reduction of scar formation on wound scar
US8319625B2 (en) * 2005-09-01 2012-11-27 Simplexgrinnell Lp Fire alarm textual notification related application
EP1940468B1 (en) * 2005-09-07 2017-11-15 AMO Regional Holdings Bi-modal hyaluronate solution
AU2006289651B2 (en) * 2005-09-07 2012-07-26 Alchemia Oncology Pty Limited Therapeutic compositions comprising hyaluronan and therapeutic antibodies as well as methods of treatment
US8598144B1 (en) 2005-11-10 2013-12-03 Reyn Pharma, Llc Method of administering hyaluronan formulation for the amelioration of osteoarthritis
US9492381B1 (en) 2005-11-10 2016-11-15 Reyn Pharma, Llc Method of administering hyaluronan formulation for preventing and ameliorating osteoarthritis
US8324192B2 (en) 2005-11-12 2012-12-04 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
US8679545B2 (en) 2005-11-12 2014-03-25 The Regents Of The University Of California Topical corticosteroids for the treatment of inflammatory diseases of the gastrointestinal tract
US8497258B2 (en) 2005-11-12 2013-07-30 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
US7722665B2 (en) * 2006-07-07 2010-05-25 Graft Technologies, Inc. System and method for providing a graft in a vascular environment
WO2008006099A2 (en) * 2006-07-07 2008-01-10 Myriad Genetics, Inc. Treatment of psychiatric disorders
AU2007295894B2 (en) 2006-09-13 2013-10-17 Enhance Skin Products, Inc. Cosmetic composition for the treatment of skin and methods thereof
PL2074141T3 (en) * 2006-09-22 2017-02-28 Novo Nordisk A/S Protease resistant insulin analogues
JP2010511713A (en) * 2006-12-05 2010-04-15 ランデック コーポレイション Drug delivery
MX2009007048A (en) * 2006-12-26 2009-07-10 Romano Dev Inc Skin lightening composition for hyperpigmented skin.
AU2008210557B2 (en) 2007-01-30 2013-08-01 Cypress Pharmaceutical, Inc. Hyaluronate compositions
EP2131849B1 (en) * 2007-03-02 2011-10-26 The University Of Wollongong Compositions and methods for delivery of anti-cancer agents
US20080268039A1 (en) * 2007-03-06 2008-10-30 Soft Gel Technologies, Inc. Loquat compositions
EP2148622A4 (en) * 2007-05-15 2013-11-27 Biotex Pharma Investments Llc Improved imaging system
US8865692B2 (en) * 2007-11-13 2014-10-21 Meritage Pharma, Inc Compositions for the treatment of gastrointestinal inflammation
CA2704957A1 (en) 2007-11-13 2009-05-22 Meritage Pharma, Inc. Compositions for the treatment of gastrointestinal inflammation
US20090123551A1 (en) * 2007-11-13 2009-05-14 Meritage Pharma, Inc. Gastrointestinal delivery systems
US20100216754A1 (en) * 2007-11-13 2010-08-26 Meritage Pharma, Inc. Compositions for the treatment of inflammation of the gastrointestinal tract
ITMI20080284A1 (en) * 2008-02-22 2009-08-23 Indena Spa ANTI-HUMAN AGENTS WITH BENZOPHENANTRIDIN STRUCTURE AND FORMULATIONS THAT CONTAIN THEM
US9260502B2 (en) 2008-03-14 2016-02-16 Novo Nordisk A/S Protease-stabilized insulin analogues
US8691759B2 (en) 2008-03-18 2014-04-08 Novo Nordisk A/S Protease stabilized, acylated insulin analogues
US20090264392A1 (en) * 2008-04-21 2009-10-22 Meritage Pharma, Inc. Treating eosinophilic esophagitis
US8163716B1 (en) 2008-06-30 2012-04-24 Smith James D Method of administering hyaluronan formulation for the amelioration of osteophytes
US8178511B1 (en) 2008-07-02 2012-05-15 Smith James D Method of administering hyaluronan formulation for the amelioration of osteopenia
IT1397247B1 (en) * 2009-05-14 2013-01-04 Fidia Farmaceutici NEW REGULATORY AGENTS OF CYTOKINIC ACTIVITY
GB0913442D0 (en) 2009-07-31 2009-09-16 Univ Ramot Cell-targeting nanoparticles comprising polynucleotide agents and uses thereof
US8273725B2 (en) 2009-09-10 2012-09-25 Genzyme Corporation Stable hyaluronan/steroid formulation
US20110172180A1 (en) 2010-01-13 2011-07-14 Allergan Industrie. Sas Heat stable hyaluronic acid compositions for dermatological use
WO2012018597A2 (en) 2010-07-26 2012-02-09 Chemotherapeutics, Llc Compositions and methods for enhancing the effectiveness of systemic, hipec, ip, and related cancer treatments
US8524662B2 (en) 2010-12-28 2013-09-03 Depuy Mitek, Llc Compositions and methods for treating joints
US8455436B2 (en) 2010-12-28 2013-06-04 Depuy Mitek, Llc Compositions and methods for treating joints
US8398611B2 (en) 2010-12-28 2013-03-19 Depuy Mitek, Inc. Compositions and methods for treating joints
US9393263B2 (en) 2011-06-03 2016-07-19 Allergan, Inc. Dermal filler compositions including antioxidants
US9408797B2 (en) 2011-06-03 2016-08-09 Allergan, Inc. Dermal filler compositions for fine line treatment
US20130096081A1 (en) 2011-06-03 2013-04-18 Allergan, Inc. Dermal filler compositions
US9149422B2 (en) 2011-06-03 2015-10-06 Allergan, Inc. Dermal filler compositions including antioxidants
TW201249843A (en) * 2011-06-14 2012-12-16 Univ Kaohsiung Medical Processes for preparing amine salts of KMUP-3 and use thereof
US8623839B2 (en) 2011-06-30 2014-01-07 Depuy Mitek, Llc Compositions and methods for stabilized polysaccharide formulations
DK2543357T3 (en) * 2011-07-07 2018-07-02 Holy Stone Healthcare Co Ltd COMPOSITION FOR USE FOR TREATMENT AND PREVENTION OF INFLAMMATION-RELATED DISORDERS
US20150359798A1 (en) * 2011-09-06 2015-12-17 Jansfat Biotechnology Co., Ltd. Piperazinyl derivative reduces high-fat diet-induced accumulation of fat in the livers, therapeutically
EP2567697A1 (en) 2011-09-12 2013-03-13 Almirall, S.A. Topical pharmaceutical compositions
TWI466675B (en) * 2011-09-16 2015-01-01 Univ China Medical Pharmaceutical composition for inhibiting inflammation
GB201118193D0 (en) 2011-10-21 2011-12-07 Jagotec Ag Improvements in or relating to oranic compounds
GB201118198D0 (en) 2011-10-21 2011-12-07 Jagotec Ag Improvements in or relating to organic compounds
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
PT2782584T (en) 2011-11-23 2021-09-02 Therapeuticsmd Inc Natural combination hormone replacement formulations and therapies
RU2497201C1 (en) * 2012-03-28 2013-10-27 Государственное бюджетное образовательное учреждение высшего профессионального образования "Курский государственный медицинский университет" Министерства здравоохранения и социального развития Российской Федерации Method for dermal flap survival growth in reduced circulation with minoxidil
RU2497200C1 (en) * 2012-03-28 2013-10-27 Государственное бюджетное образовательное учреждение высшего профессионального образования "Курский государственный медицинский университет" Министерства здравоохранения и социального развития Российской Федерации Method for pharmacological correction of sceletal muscle ischemia with minoxidil
AU2013250767A1 (en) 2012-04-18 2014-10-09 Quiet Therapeutics Ltd. Lipidated glycosaminoglycan particles for the delivery of nucleic acids
ITPD20120173A1 (en) 2012-05-31 2013-12-01 Fidia Farmaceutici "NEW HYDROPHOBIC PROTEIN RELEASE SYSTEM"
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
ITMI20121316A1 (en) 2012-07-27 2014-01-28 Altergon Sa CONDROTIC COMPLEXES FOR TRANSCUTANEOUS ABSORPTION
FR2994846B1 (en) 2012-08-29 2014-12-26 Vivacy Lab COMPOSITION, STERILIZED, COMPRISING AT LEAST ONE HYALURONIC ACID AND MAGNESIUM ASCORBYL PHOSPHATE
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
FR3000670B1 (en) * 2013-01-10 2015-02-27 Oreal SOOTHING COSMETIC COMPOSITION BASED ON SALICYLIC ACID.
WO2014159060A1 (en) 2013-03-14 2014-10-02 Hallux, Inc. Method of treating infections, diseases or disorders of nail unit
WO2014165713A2 (en) 2013-04-03 2014-10-09 Cedars-Sinai Medical Center Treatment of inflammatory conditions by modulation of hyaluronan and hyaluronidase activity
GR1008308B (en) 2013-05-31 2014-10-02 UNI-PHARMA ΚΛΕΩΝ ΤΣΕΤΗΣ ΦΑΡΜΑΚΕΥΤΙΚΑ ΕΡΓΑΣΤΗΡΙΑ ΑΒΕΕ με δ.τ. "UNI-PHARMA ABEE", Local pharmaceutical and medi-tech compositions containing combinations of sucralfat, hyaluronic acid, arginine and one natural moistening factor
KR101439032B1 (en) * 2013-06-13 2014-09-05 동아에스티 주식회사 Pharmaceutical composition containing piroxicam and hyaluronic acid for the treatment of osteoarthritis
CN103330945B (en) * 2013-07-16 2014-07-02 山东大学齐鲁医院 Application of pingyangmycin combined with sodium hyaluronate in drug for treating lymphatic malformation
CN103341157A (en) * 2013-07-25 2013-10-09 山东大学齐鲁医院 Application of pingyangmycin combined sodium hyaluronate in medicine for treating venous malformation
DK3055325T3 (en) 2013-10-07 2018-04-16 Novo Nordisk As New derivative of an insulin analogue
AR100562A1 (en) 2014-05-22 2016-10-12 Therapeuticsmd Inc PHARMACEUTICAL COMPOSITION OF ESTRADIOL AND PROGESTERONE FOR HORMONAL REPLACEMENT THERAPY
JP2017520549A (en) 2014-06-26 2017-07-27 ラモット アット テル アビブ ユニバーシティ， リミテッド Liposome formulation for delivery of nucleic acids
US9682099B2 (en) 2015-01-20 2017-06-20 DePuy Synthes Products, Inc. Compositions and methods for treating joints
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
CA3020153A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
WO2017173044A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd Inc. Steroid hormone compositions in medium chain oils
CN110087674B (en) 2016-12-16 2023-01-03 诺和诺德股份有限公司 Pharmaceutical composition containing insulin
WO2019173261A1 (en) * 2018-03-06 2019-09-12 Samuel Asculai Composition and method to treat cancer using hyaluronic acid
CN109512825A (en) * 2018-12-29 2019-03-26 江苏靶标生物医药研究所有限公司 A kind of composition and its application of platinum-like compounds and Sodium Hyaluronate
CN110467689A (en) * 2019-09-09 2019-11-19 山东众山生物科技有限公司 A kind of derivatives of hyaluronic acids and preparation method thereof
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0138572A2 (en) * 1983-10-11 1985-04-24 FIDIA S.p.A. Hyaluronic acid fractions having pharmaceutical activity, methods for preparation thereof, and pharmaceutical compositions containing the same
EP0197718A2 (en) * 1985-04-05 1986-10-15 FIDIA S.p.A. New medicaments for topical use
EP0216453A2 (en) * 1985-07-08 1987-04-01 FIDIA S.p.A. Esters of hyaluronic acid and their salts.
EP0224987A2 (en) * 1985-11-29 1987-06-10 Biomatrix, Inc. Drug delivery systems based on hyaluronan, derivatives thereof and their salts and method of producing same
JPS62240628A (en) * 1986-03-26 1987-10-21 Kao Corp Endermic absorption promoter and external preparation containing same
EP0245126A2 (en) * 1986-05-07 1987-11-11 Taro Ogiso Percutaneous absorption preparation and process for preparing same
US4711780A (en) * 1984-06-11 1987-12-08 Fahim Mostafa S Composition and process for promoting epithelial regeneration
EP0265116A2 (en) * 1986-10-13 1988-04-27 FIDIA S.p.A. Cross-linked esters of hyaluronic acid
EP0287210A2 (en) * 1987-03-13 1988-10-19 Medical Research International Limited Therapeutic compositions
EP0380367A1 (en) * 1989-01-27 1990-08-01 Stafford-Miller Ltd. Compositions and method for the treatment of disease

Family Cites Families (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2583096A (en) * 1949-01-15 1952-01-22 Searle & Co Process for the production of high viscosity hyaluronic acid
GB769287A (en) * 1954-08-18 1957-03-06 American Home Prod Preparation of partially depolymerized hyaluronic acid and therapeutic compositions thereof
FR3715M (en) * 1964-06-11 1965-11-29 Lucien Nouvel Improved antithermics and antirheumatic drugs.
US3887703A (en) * 1967-03-24 1975-06-03 Oreal Mucopolysaccharides, their preparation and use in cosmetic and pharmaceutical compositions
GB1283892A (en) * 1970-06-08 1972-08-02 Irwin Irville Lubowe Improvements in and relating to medicinal compositions for application to the skin and/or hair
DE2364373A1 (en) * 1973-12-22 1975-07-10 Hahn Carl Dr Gmbh Pharmaceutical and/or cosmetic prepns. - contg. methyl-substd. xanthine, oestriol and/or a mucopolysaccharide
US4141973A (en) * 1975-10-17 1979-02-27 Biotrics, Inc. Ultrapure hyaluronic acid and the use thereof
US4282216A (en) * 1977-04-20 1981-08-04 Johnson & Johnson Topical anti-inflammatory drug therapy
US4296104A (en) * 1979-08-30 1981-10-20 Herschler R J Therapeutic dimethyl sulfoxide composition and methods of use
US4272522A (en) * 1979-10-15 1981-06-09 Balazs Endre A Method for stimulating phagocytic activity and synergistic compositions therefor
US4303676A (en) * 1980-03-21 1981-12-01 Balazs Endre A Hyaluronate based compositions and cosmetic formulations containing same
JPS57183707A (en) * 1981-05-02 1982-11-12 Shiseido Co Ltd Cosmetic
US4684627A (en) * 1981-09-08 1987-08-04 Leveen Harry H Treatment of cancer with phlorizin and its derivatives
US5166331A (en) * 1983-10-10 1992-11-24 Fidia, S.P.A. Hyaluronics acid fractions, methods for the preparation thereof, and pharmaceutical compositions containing same
US4582685A (en) 1982-10-07 1986-04-15 Helena Laboratories Corporation Test kit for performing a medical test
US4711884A (en) * 1983-02-28 1987-12-08 E. R. Squibb & Sons, Inc. Thiazine and thiazepine containing compounds
AU555747B2 (en) * 1983-08-09 1986-10-09 Cilco Inc. Chondroitin sulfate and sodium hyaluronate composition
AU570998B2 (en) * 1983-09-07 1988-03-31 Takeda Chemical Industries Ltd. Topical steroid compositions for acne
CA1295796C (en) * 1984-03-27 1992-02-18 Conrad Whyne Biodegradable matrix and methods for producing same
CH663353A5 (en) * 1984-03-28 1987-12-15 Joaquin Amat Larraz AGENT AGAINST CANCER.
US4716224A (en) * 1984-05-04 1987-12-29 Seikagaku Kogyo Co. Ltd. Crosslinked hyaluronic acid and its use
JPS6117A (en) * 1984-06-11 1986-01-06 Seikagaku Kogyo Co Ltd Mucopolysaccharide-type cancer-metastatis suppressing agent
US4735902A (en) * 1984-10-23 1988-04-05 Matti Siren Stabilized composition containing inositoltriphosphate
US4582865A (en) * 1984-12-06 1986-04-15 Biomatrix, Inc. Cross-linked gels of hyaluronic acid and products containing such gels
US4636524A (en) * 1984-12-06 1987-01-13 Biomatrix, Inc. Cross-linked gels of hyaluronic acid and products containing such gels
EP0187703B1 (en) * 1985-01-11 1992-08-05 Teijin Limited Sustained release preparation
JPS61233622A (en) * 1985-04-09 1986-10-17 Riken Vitamin Co Ltd Eye lotion composition
SE8501723L (en) * 1985-04-09 1986-10-10 Pharmacia Ab PREPARATION TO BE USED IN TREATMENT OF LED INFLAMMATION
US4725585A (en) * 1985-04-26 1988-02-16 Pharmacia Ab Method of enhancing the host defense
US4725852A (en) 1985-05-09 1988-02-16 Burlington Industries, Inc. Random artificially perturbed liquid apparatus and method
IT1214609B (en) * 1985-05-17 1990-01-18 Opocrin Spa HEXOSAMINOGLICANS DEPOLYMERIZED SULPHATES FOR ANTI-THROMBOTIC, FIBRINOLITHIC, ANTI-INFLAMMATORY ACTIVITIES, THEIR PREPARATION PROCEDURE AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
DE3676235D1 (en) * 1985-06-04 1991-01-31 Teijin Ltd DRUG PREPARATION WITH DELAYED DELIVERY OF ACTIVE SUBSTANCE.
US4617319A (en) * 1985-06-13 1986-10-14 American Cyanamid Company Method of treating multiple sclerosis
FR2584606A1 (en) * 1985-07-12 1987-01-16 Dropic USE OF POLY- AND OLIGOSACCHARIDES FOR THE PRODUCTION OF ACTIVE MEDICAMENTS IN THE PATHOLOGIES OF CONNECTIVE TISSUE
IN166447B (en) * 1985-11-27 1990-05-12 Ethicon Inc
JP2604135B2 (en) * 1986-02-28 1997-04-30 ライオン株式会社 Oral bone disease treatment
US5262403A (en) * 1986-03-10 1993-11-16 Board Of Regents, The University Of Texas System Glycosaminoglycan derivatives and their use as inhibitors of tumor invasiveness of metastatic profusion-II
JPS62212335A (en) * 1986-03-14 1987-09-18 Mitsui Toatsu Chem Inc 2-aryl-2-methylpropyl ether derivative and insecticide containing said derivative as active component
EP0240098A3 (en) * 1986-04-04 1989-05-10 Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo Oligo and polysaccharides for the treatment of diseases caused by retroviruses
JPS6345223A (en) * 1986-04-04 1988-02-26 Ueno Seiyaku Oyo Kenkyusho:Kk Remedy for retrovirus disease
US4808576A (en) * 1986-04-28 1989-02-28 Mobay Corporation Remote administration of hyaluronic acid to mammals
EP0244178A3 (en) * 1986-04-28 1989-02-08 Iolab, Inc Intraocular dosage compositions and method of use
IT1189111B (en) * 1986-05-08 1988-01-28 Minnesota Mining & Mfg RADIOGRAPHIC ELEMENTS WITH A REDUCED CROSS-OVER AND REDUCED RESIDUAL COLORING
JPS62287041A (en) * 1986-06-05 1987-12-12 Kawasaki Steel Corp Production of high-alloy steel sintered material
US4946870A (en) * 1986-06-06 1990-08-07 Union Carbide Chemicals And Plastics Company Inc. Delivery systems for pharmaceutical or therapeutic actives
JPS6311678A (en) 1986-06-30 1988-01-19 Hitachi Chem Co Ltd Electroless copper plating method
JPH0725689B2 (en) * 1986-10-07 1995-03-22 中外製薬株式会社 Sustained-release preparation containing granulocyte colony-stimulating factor
JPH07110349B2 (en) * 1986-11-04 1995-11-29 セイレイ工業株式会社 Paddy sorting device
NZ222695A (en) * 1986-11-29 1990-03-27 Ueno Seiyaku Oyo Kenkyujo Kk Synergistic antiviral compositions
EP0270319A3 (en) * 1986-12-03 1990-03-28 Logistics Data Systems, Inc. Video c.a.d. system
US5385938B1 (en) * 1986-12-23 1997-07-15 Tristrata Inc Method of using glycolic acid for treating wrinkles
EP0356435B1 (en) * 1987-03-19 1995-10-18 Arthropharm Pty. Limited Anti-inflammatory compounds and compositions
EP0285357A3 (en) * 1987-03-31 1989-10-25 Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo Control of retroviruses
US4795741A (en) * 1987-05-06 1989-01-03 Biomatrix, Inc. Compositions for therapeutic percutaneous embolization and the use thereof
US5079236A (en) * 1987-05-27 1992-01-07 Hyal Pharmaceutical Corporation Pure, sterile, pyrogen-free hyaluronic acid formulations their methods of preparation and methods of use
GB8713662D0 (en) * 1987-06-11 1987-07-15 Skandigen Ab Hyaluronic acid derivatives
GB8713747D0 (en) * 1987-06-12 1987-07-15 Unilever Plc Skin treatment composition
GB8715242D0 (en) * 1987-06-29 1987-08-05 Wood E M Fenclofenac as immunosuppressant drug
PT87886B (en) * 1987-07-01 1993-09-30 Genentech Inc METHOD FOR PREVENTING FIBRIN DEPOSITION OR ADHESION FORMATION AND PROCESS FOR THE PREPARATION OF THERAPEUTIC COMPOSITIONS FOR THAT END
US4900550A (en) * 1987-08-19 1990-02-13 Amy Allene Cosmetiques, Inc. Skin care cosmetic regime
KR920003601B1 (en) * 1987-09-03 1992-05-04 유니버시티 어브 죠지아 리서취 화운데이션 인코포레이티드 Ocular cyclosporin composition
EP0307097B1 (en) * 1987-09-08 1993-06-09 Takeda Chemical Industries, Ltd. Water-insolubilized cytokines
NZ226171A (en) * 1987-09-18 1990-06-26 Ethicon Inc Gel formulation containing polypeptide growth factor
HU203198B (en) * 1987-10-26 1991-06-28 Sandoz Ag Process for producing pharmaceutical compositions having immunity-inhibiting, monokin-, particularly interleukin-1-inhibiting effect
JPH01151462A (en) * 1987-12-09 1989-06-14 Terumo Corp Fluid for peritoneal perfusion
DK505488D0 (en) * 1987-12-21 1988-09-09 Bar Shalom Daniel MEDIUM AND USE OF SAME
DK505588D0 (en) * 1988-02-26 1988-09-09 Jesper Hamburger MEDIUM AND USE OF SAME
US4943560A (en) * 1988-04-06 1990-07-24 Regents Of The University Of Minnesota Solvent system for chronic vascular infusion of hydrophobic drugs
JPH01265970A (en) * 1988-04-19 1989-10-24 Shiseido Co Ltd Collagen water solution or water dispersion solution including hyaluronic acid
US4840341A (en) 1988-05-09 1989-06-20 Hasegawa Gary K Clip and holder
IT1219587B (en) * 1988-05-13 1990-05-18 Fidia Farmaceutici SELF-CROSS-LINKED CARBOXYLY POLYSACCHARIDES
JPH01287041A (en) * 1988-05-13 1989-11-17 Rooman Kogyo:Kk Sustained release preparation
US5135915A (en) * 1988-10-14 1992-08-04 Genentech, Inc. Method for the treatment of grafts prior to transplantation using TGF-.beta.
DE3900198A1 (en) * 1989-01-05 1990-07-12 Merck Patent Gmbh TOPIC APPLICABLE PHARMACEUTICAL PREPARATION
US5156846A (en) * 1989-02-23 1992-10-20 University Of Utah Percutaneous drug delivery system
US4996193A (en) * 1989-03-03 1991-02-26 The Regents Of The University Of California Combined topical and systemic method of administration of cyclosporine
US5053222A (en) * 1989-06-07 1991-10-01 Shiseido Company Ltd. Hair cosmetic composition
CA1340994C (en) * 1989-09-21 2000-05-16 Rudolf Edgar Dr. Falk Treatment of conditions and disease
US5095037B1 (en) * 1989-12-21 1995-12-19 Nissho Kk Combined anti-inflammatory agent
US5181276A (en) * 1990-02-22 1993-01-26 Baxter International Inc. Infection resistant products
US5290271A (en) * 1990-05-14 1994-03-01 Jernberg Gary R Surgical implant and method for controlled release of chemotherapeutic agents
US5091182A (en) * 1990-07-23 1992-02-25 Syntex (U.S.A.) Inc. Dispensing units for ketorolac topical gel formlations
US5234914A (en) * 1991-06-11 1993-08-10 Patent Biopharmaceutics, Inc. Methods of treating hemorrhoids and anorecial disease
EP0804931B1 (en) * 1992-02-04 2003-05-07 Baxter International Inc. Peritoneal dialysis solutions and their use to minimize injury to mesothelial cells

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0138572A2 (en) * 1983-10-11 1985-04-24 FIDIA S.p.A. Hyaluronic acid fractions having pharmaceutical activity, methods for preparation thereof, and pharmaceutical compositions containing the same
US4711780A (en) * 1984-06-11 1987-12-08 Fahim Mostafa S Composition and process for promoting epithelial regeneration
EP0197718A2 (en) * 1985-04-05 1986-10-15 FIDIA S.p.A. New medicaments for topical use
EP0216453A2 (en) * 1985-07-08 1987-04-01 FIDIA S.p.A. Esters of hyaluronic acid and their salts.
EP0224987A2 (en) * 1985-11-29 1987-06-10 Biomatrix, Inc. Drug delivery systems based on hyaluronan, derivatives thereof and their salts and method of producing same
JPS62240628A (en) * 1986-03-26 1987-10-21 Kao Corp Endermic absorption promoter and external preparation containing same
EP0245126A2 (en) * 1986-05-07 1987-11-11 Taro Ogiso Percutaneous absorption preparation and process for preparing same
EP0265116A2 (en) * 1986-10-13 1988-04-27 FIDIA S.p.A. Cross-linked esters of hyaluronic acid
EP0287210A2 (en) * 1987-03-13 1988-10-19 Medical Research International Limited Therapeutic compositions
EP0380367A1 (en) * 1989-01-27 1990-08-01 Stafford-Miller Ltd. Compositions and method for the treatment of disease

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CHEMICAL ABSTRACTS, vol. 76, no. 10, 6 March 1972, Columbus, Ohio, US; abstract no. 49897F, SNEADER W. E. ET AL: "Possible mechanism for the action of dimethyl sulfoxide on percutaneous absorption" page 273; *
DATABASE WPI Derwent World Patents Index; AN 87-337226 *
J. PHARM., PHAMACOL., vol. 23 SUPPL, 1971, pages 252S *

Also Published As

Publication number Publication date
SK459890A3 (en) 2000-09-12
DE69034018D1 (en) 2002-12-19
LT3545B (en) 1995-11-27
DK0445255T4 (en) 2002-02-18
NO911952L (en) 1991-07-05
DE69024039D1 (en) 1996-01-18
HK1005985A1 (en) 1999-02-05
HU907339D0 (en) 1991-08-28
CN1051503A (en) 1991-05-22
RU2146139C1 (en) 2000-03-10
HUT64699A (en) 1994-02-28
EP0445255A1 (en) 1991-09-11
US6069135A (en) 2000-05-30
EP0656213B1 (en) 2002-11-13
US5811410A (en) 1998-09-22
NO911952D0 (en) 1991-05-21
HU211953A9 (en) 1996-01-29
IN171745B (en) 1992-12-26
ES2080837T5 (en) 2002-03-01
AU1485097A (en) 1997-05-22
KR920700697A (en) 1992-08-10
SG49658A1 (en) 1998-06-15
US20040019011A1 (en) 2004-01-29
AU6433090A (en) 1991-04-18
CN1101228C (en) 2003-02-12
US5985850A (en) 1999-11-16
AU674894C (en) 2002-03-14
FI912470A0 (en) 1991-05-21
AU5227493A (en) 1994-03-03
CA2042034A1 (en) 1991-03-22
AU674894B2 (en) 1997-01-16
DE69024039T2 (en) 1996-06-13
DE69024039T3 (en) 2002-12-12
US5852002A (en) 1998-12-22
EP0656213A1 (en) 1995-06-07
ATE227587T1 (en) 2002-11-15
IL95745A0 (en) 1991-06-30
AP9000206A0 (en) 1990-10-31
HU220758B1 (en) 2002-05-28
ES2080837T3 (en) 1996-02-16
ZA907564B (en) 1991-08-28
JPH04504579A (en) 1992-08-13
ATE131068T1 (en) 1995-12-15
US6194392B1 (en) 2001-02-27
RO112812B1 (en) 1998-01-30
ES2186693T3 (en) 2003-05-16
BR9006924A (en) 1991-12-10
WO1991004058A2 (en) 1991-04-04
IL95745A (en) 1999-09-22
US5929048A (en) 1999-07-27
US5830882A (en) 1998-11-03
JP3256761B2 (en) 2002-02-12
US5914314A (en) 1999-06-22
DK0656213T3 (en) 2003-03-17
US5932560A (en) 1999-08-03
HK44797A (en) 1997-04-18
DE69034018T2 (en) 2003-07-24
LTIP1582A (en) 1995-06-26
DK0445255T3 (en) 1996-03-04
US20060128655A1 (en) 2006-06-15
US5827834A (en) 1998-10-27
CA1340994C (en) 2000-05-16
EP0445255B2 (en) 2001-12-05
US6048844A (en) 2000-04-11
AP175A (en) 1992-04-03
US5985851A (en) 1999-11-16
EP0445255B1 (en) 1995-12-06

Similar Documents

Publication Publication Date Title
WO1991004058A3 (en) Treatment of conditions and disease
AU576365B2 (en) Collagen and or fibrinogen as carrier of drugs for their introduction into cellular lesion areas
CA2314326A1 (en) Transdermal therapeutic device and method with capsaicin and capsaicin analogs
EP0333606A3 (en) Preparation of t-cell and t-cell membrane for use in prevention and treatment of autoimmune diseases
CS9004859A2 (en) Method of adhesive plaster production that contains oestrogen as active substance
BR9306841A (en) Pharmaceutical composition process for providing an antihistamine treatment which does not induce any significant cardiac arrhythmia in a human patient and use of a composition for the manufacture of a medicine for use in an antihistamine treatment
PH23867A (en) Method of treating parkinson's disease using indolone derivatives
EP0489108A4 (en) Method and composition for the treatment of cutaneous, ocular, and mucosal hypersensitivity, inflammation, and hyperproliferative conditions using topical preparations of serotonin antagonists
CA2214503A1 (en) Method for treating tumors
WO1999024074A3 (en) Novel conjugates of opioids and endogenous carriers
EP1733734A3 (en) Placental alkaline phosphatase to control diabetes
AU8091787A (en) The use of paroxetine to treat pain
Jönson et al. Vagal stimulation of duodenal HCO3‐secretion in anaesthetized rats
WO1994006449A3 (en) Morphogen-induced liver regeneration
WO1996030042A3 (en) Methods of treating inflammation and compositions therefor
EP1304108A3 (en) Anti-arrhythmic composition and methods of treatment
GB9023701D0 (en) Medical treatment
AU6932691A (en) Administration method of antithrombin
Jewell et al. Heparin and ethyl biscoumacetate in prevention of experimental venous thrombosis
AU1656997A (en) Use of alpha1-adrenoreceptor antagonists in the prevention and treatment of cancer
AU6069794A (en) Method and compositions for noninvasive dose to effect administration of lipophilic drugs
WO2000013701A3 (en) Angiogenically effective unit dose of fgf-2 and method of use
GR3032224T3 (en) Therapeutic agent for threatened abortion.
WO1997026880A3 (en) Use of a combination of delavirdine and one or more protease inhibitors in hiv-1 infected patients
SE8804640L (en) MEDICINAL COMPREHENSIVE CYCLOLINOPEPTIDE A

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AT AU BB BG BR CA CH DE DK ES FI GB HU JP KP KR LK LU MC MG MW NL NO RO SD SE SU US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE BF BJ CF CG CH CM DE DK ES FR GA GB IT LU ML MR NL SE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2042034

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1990914108

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 912470

Country of ref document: FI

WWP Wipo information: published in national office

Ref document number: 1990914108

Country of ref document: EP

AK Designated states

Kind code of ref document: A3

Designated state(s): AT AU BB BG BR CA CH DE DK ES FI GB HU JP KP KR LK LU MC MG MW NL NO RO SD SE SU US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE BF BJ CF CG CH CM DE DK ES FR GA GB IT LU ML MR NL SE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 148511

Country of ref document: RO

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWG Wipo information: grant in national office

Ref document number: 1990914108

Country of ref document: EP

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)